688062.SH
迈威生物-U
SSE · Healthcare · Biotechnology · CN
CNY 29.23
−6.22%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 745.3M | 662.5M | 199.8M | 127.8M | 27.7M |
| Cost of Revenue | 84.9M | 64.5M | 29.0M | 1.4M | 70.6K |
| Gross Profit | 660.4M | 598.1M | 170.8M | 126.5M | 27.7M |
| Operating Expenses | |||||
| R&D Expense | 932.9M | 977.0M | 782.9M | 835.8M | 758.6M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 276.0M | 268.6M | 213.5M | 225.4M | 189.1M |
| Selling & Marketing Expense | 249.4M | 225.3M | 191.7M | 142.9M | 78.5M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 1.6B | 1.6B | 1.2B | 1.2B | 993.3M |
| Cost and Expenses | 1.7B | 1.6B | 1.3B | 1.2B | 993.4M |
| Operating Income (EBIT) | (903.2M) | (955.3M) | (1.0B) | (1.1B) | (958.1M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (904.1M) | (956.4M) | (1.0B) | (1.1B) | (958.1M) |
| Income Tax Expense | 18.7M | 15.9M | (906.8K) | 3.5M | — |
| Bottom Line | |||||
| Net Income | (919.5M) | (969.3M) | (1.0B) | (1.1B) | (955.2M) |
| Earnings from Cont. Ops | (922.8M) | (972.3M) | (1.0B) | (1.1B) | (958.0M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (919.5M) | (969.3M) | (1.0B) | (1.1B) | (955.2M) |
| Per Share | |||||
| Basic EPS | (CN¥2.31) | (CN¥2.43) | (CN¥2.61) | (CN¥2.64) | (CN¥2.44) |
| Diluted EPS | (CN¥2.31) | (CN¥2.43) | (CN¥2.61) | (CN¥2.64) | (CN¥2.44) |
| Revenue Per Share | CN¥1.88 | CN¥1.66 | CN¥0.50 | CN¥0.32 | CN¥0.07 |
| Shares | |||||
| Basic Shares Outstanding | 396.6M | 398.9M | 400.0M | 399.0M | 391.5M |
| Diluted Shares Outstanding | 396.6M | 398.9M | 400.0M | 399.0M | 391.5M |
| Profitability Metrics | |||||
| EBITDA | — | (767.7M) | (929.6M) | (973.0M) | (887.1M) |
| D&A | — | 187.6M | 113.9M | 79.6M | 71.0M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026